Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Intraocular lens guidance

This article was originally published in The Gray Sheet

Executive Summary

Clinical studies comparing an investigational IOL to a historical control should have a minimum of 300 subjects, while certain modifications to approved devices would require 100 subjects (1"The Gray Sheet," July 26, p. 6), according to the agency's draft "Intraocular Lens Guidance." Comments are due by Jan. 12, 2000

You may also be interested in...

Revised IOL Guidance Requires 100-Patient Study For Some Design Changes

"Level B" modifications to intraocular lenses (IOLs) would require a 100-subject confirmatory study in addition to preclinical data, under FDA's draft "Intraocular Lens Guidance Document" posted July 16 on the agency's website.

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts